Alemtuzumab and Combination Chemotherapy Followed By Donor Lymphocytes in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer

Yale University

Status and phase

Completed

Phase 1

Conditions

Chronic Myeloproliferative Disorders

Lymphoma

Leukemia

Myelodysplastic Syndromes

Myelodysplastic/Myeloproliferative Neoplasms

Treatments

Biological: alemtuzumab

Biological: therapeutic allogeneic lymphocytes

Drug: melphalan

Procedure: peripheral blood stem cell transplantation

Drug: thiotepa

Drug: fludarabine phosphate

Drug: tacrolimus

Study type

Interventional

Funder types

Other

NIH

Identifiers

NCT00104975

NCI-6765

YALE-25971

CDR0000413698

Details and patient eligibility

About

RATIONALE: Giving low doses of chemotherapy before a donor peripheral blood stem cell transplant helps stop the growth of cancer cells. It also stops the patient's immune system from rejecting the donor's stem cells. The donated stem cells may replace the patient's immune system and help destroy any remaining cancer cells (graft-versus-tumor effect). Giving an infusion of the donor's T cells that have been treated in the laboratory after the transplant may help increase this effect. Sometimes the transplanted cells from a donor can also make an immune response against the body's normal cells. Giving tacrolimus before and after transplant may stop this from happening.

PURPOSE: This phase I trial is studying the side effects and best dose of donor lymphocytes when given after alemtuzumab and combination chemotherapy in treating patients who are undergoing donor stem cell transplant for hematologic cancer.

Full description

OBJECTIVES:

Determine the feasibility and efficacy of a reduced-intensity conditioning regimen comprising alemtuzumab, fludarabine, melphalan, and thiotepa followed by allogeneic peripheral blood stem cell transplantation (PBSCT) in patients with hematologic malignancies.
Determine the toxicity of this regimen in these patients.
Determine the safety of LMB-2 immunotoxin-treated, selectively-depleted donor T cells, administered after allogeneic PBSCT, in these patients.

OUTLINE: This is a dose-escalation study of LMB-2 immunotoxin-treated, selectively-depleted donor T cells.

T cell preparation: Patients and donors undergo apheresis to obtain peripheral blood mononuclear cells (PBMCs), which are expanded in culture. Patients' PBMCs are irradiated and mixed with donor PBMCs. LMB-2 immunotoxin is added to the PBMCs in order to selectively deplete T cells from the donor PBMCs.
Conditioning: Patients receive alemtuzumab IV over 2 hours on days -9 to -5, fludarabine IV over 30 minutes on days -8 to -5, melphalan IV over 15-20 minutes on day -4, and thiotepa IV on days -3 to -2.
Immunosuppression: Patients receive tacrolimus IV continuously on days -10 to 1.
Allogeneic peripheral blood stem cell (PBSC) transplantation: Patients undergo allogeneic PBSC transplantation on day 0.
LMB-2 immunotoxin-treated, selectively-depleted donor T cells: Patients receive LMB-2 immunotoxin-treated, selectively-depleted donor T cells IV over 30-60 minutes on approximately day 28.

Cohorts of 3-6 patients receive escalating dose of LMB-2 immunotoxin-treated, selectively-depleted donor T cells until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 6 patients experience dose-limiting-toxicity.

After completion of study treatment, patients are followed weekly for 100 days post-transplantation and then periodically for survival.

PROJECTED ACCRUAL: A total of 15-20 patients will be accrued for this study.

Enrollment

20 estimated patients

Sex

All

Ages

18 to 55 years old

Volunteers

No Healthy Volunteers

Inclusion and exclusion criteria

DISEASE CHARACTERISTICS:

Diagnosis of 1 of the following hematologic malignancies:
- Chronic myelogenous leukemia
  - Accelerated phase or blast phase
- Acute myeloid leukemia, meeting any of the following criteria:
  - In second or subsequent remission
  - In primary induction failure
  - In partial remission
  - In resistant relapse
- Chronic lymphocytic leukemia
  - In Richter's transformation
- High-grade non-Hodgkin's lymphoma
  - Refractory to standard treatment
- Myeloproliferative disorders
  - Undergoing transformation to terminal stages
- Myelodysplastic syndromes (MDS), including any of the following:
  - Refractory anemia with excess blasts
  - Transformation to acute leukemia
  - MDS secondary to chemotherapy
Partially-matched related family donor available
- One HLA haplotype match
No HLA-matched (10/10 or 9/10) sibling donor or unrelated donor available NOTE: A new classification scheme for adult non-Hodgkin's lymphoma has been adopted by PDQ. The terminology of "indolent" or "aggressive" lymphoma will replace the former terminology of "low", "intermediate", or "high" grade lymphoma. However, this protocol uses the former terminology.

PATIENT CHARACTERISTICS:

Age

18 to 55

Performance status

ECOG 0-1

Life expectancy

Not specified

Hematopoietic

Not specified

Hepatic

SGOT and SGPT < 3 times upper limit of normal (ULN)
No active or persistent viral hepatitis

Renal

Creatinine < 2.0 mg/dL* OR
Creatinine clearance > 60 mL/min* NOTE: *Unless due to malignancy

Cardiovascular

LVEF ≥ 45%

Pulmonary

DLCO ≥ 60% of predicted* (corrected for hemoglobin) NOTE: *Unless patient is given clearance by a pulmonary consultation

Other

Not pregnant or nursing
Negative pregnancy test
Fertile patients must use effective contraception during and for up to 2 years after completion of study treatment
HIV negative
Human T cell lymphotrophic virus type 1 negative
No serious co-morbid medical condition
No other medical condition that would preclude study compliance

PRIOR CONCURRENT THERAPY:

Biologic therapy